^
Association details:
| Biomarker: | MUC16 mutation |
|---|---|
| Cancer: | Melanoma |
| Drug: | AiRuiKa (camrelizumab) (PD1 inhibitor) + AiTan (rivoceranib) (VEGFR-2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Apatinib combined with camrelizumab in advanced acral melanoma patients: An open-label, single-arm phase 2 trial
Published date:
01/11/2023
Excerpt:
Here, a phase II trial was performed to explore the safety and efficacy of apatinib combined with camrelizumab in advanced acral melanoma patients as first-line therapy (NCT03955354)….The TMB High rates were 80.0% (4/5) versus 38.4% (5/13) in Re group versus un Re group. According to survival status, a gene set containing TTN, MUC16, VPS13D, ALPK2 and SCUBE1 was established, which was considered positive when at least one gene was altered (Table 3). Patients with gene-set positive showed markedly better PFS and OS than those with gene-set negative in this cohort
DOI:
10.1016/j.ejca.2022.12.027
Trial ID:
